van der Schoot CE - Search Results

1

Peripheral Stem Cell Apheresis is Feasible Post ¹³¹Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution.

Kraal KCJM, Timmerman I, Kansen HM, van den Bos C, Zsiros J, van den Berg H, Somers S, Braakman E, Peek AML, van Noesel MM, van der Schoot CE, Fiocco M, Caron HN, Voermans C, Tytgat GAM. Kraal KCJM, et al. Among authors: van den bos c, van den berg h, van noesel mm, van der schoot ce. Clin Cancer Res. 2019 Feb 1;25(3):1012-1021. doi: 10.1158/1078-0432.CCR-18-1904. Epub 2018 Oct 12. Clin Cancer Res. 2019. PMID: 30314967

2

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

van der Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schorangel JH, Richel DJ, Rutgers EJ, Slaper-Cortenbach IC, van der Schoot CE, Rodenhuis S. van der Wall E, et al. Among authors: van der schoot ce. Br J Cancer. 1995 Apr;71(4):857-62. doi: 10.1038/bjc.1995.165. Br J Cancer. 1995. PMID: 7536025 Free PMC article. Clinical Trial.

3

Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation.

Dercksen MW, Rodenhuis S, Dirkson MK, Schaasberg WP, Baars JW, van der Wall E, Slaper-Cortenbach IC, Pinedo HM, Von dem Borne AE, van der Schoot CE, et al. Dercksen MW, et al. Among authors: van der wall e, van der schoot ce. J Clin Oncol. 1995 Aug;13(8):1922-32. doi: 10.1200/JCO.1995.13.8.1922. J Clin Oncol. 1995. PMID: 7543561

4

Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.

Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE. Steenbergen EJ, et al. Among authors: van den berg h, van der schoot ce, van leeuwen ef. Leukemia. 1995 Oct;9(10):1726-34. Leukemia. 1995. PMID: 7564517

5

Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells across uncoated or fibronectin-coated filters.

Voermans C, Gerritsen WR, von dem Borne AE, van der Schoot CE. Voermans C, et al. Among authors: van der schoot ce. Exp Hematol. 1999 Dec;27(12):1806-14. doi: 10.1016/s0301-472x(99)00113-7. Exp Hematol. 1999. PMID: 10641598 Free article.

6

Comparison of single and dual-platform assay formats for CD34+ haematopoietic progenitor cell enumeration.

Gratama JW, Braakman E, Kraan J, Lankheet P, Levering WH, Van Den Beemd MW, Van Der Schoot CE, Wijermans P, Preijers F. Gratama JW, et al. Among authors: van der schoot ce, van den beemd mw. Clin Lab Haematol. 1999 Oct;21(5):337-46. doi: 10.1046/j.1365-2257.1999.00236.x. Clin Lab Haematol. 1999. PMID: 10646076

7

Adhesion molecules involved in transendothelial migration of human hematopoietic progenitor cells.

Voermans C, Rood PM, Hordijk PL, Gerritsen WR, van der Schoot CE. Voermans C, et al. Among authors: van der schoot ce. Stem Cells. 2000;18(6):435-43. doi: 10.1634/stemcells.18-6-435. Stem Cells. 2000. PMID: 11072032

8

In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation.

Voermans C, Kooi ML, Rodenhuis S, van der Lelie H, van der Schoot CE, Gerritsen WR. Voermans C, et al. Among authors: van der lelie h, van der schoot ce. Blood. 2001 Feb 1;97(3):799-804. doi: 10.1182/blood.v97.3.799. Blood. 2001. PMID: 11157500 Free article.

9

Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.

de Haas V, Oosten L, Dee R, Verhagen OJ, Kroes W, van den Berg H, van der Schoot CE. de Haas V, et al. Among authors: van den berg h, van der schoot ce. Br J Haematol. 2000 Dec;111(4):1080-6. doi: 10.1046/j.1365-2141.2000.02434.x. Br J Haematol. 2000. PMID: 11167743 Free article.

10

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

de Haas V, Verhagen OJ, von dem Borne AE, Kroes W, van den Berg H, van der Schoot CE. de Haas V, et al. Among authors: van den berg h, van der schoot ce. Leukemia. 2001 Jan;15(1):134-40. doi: 10.1038/sj.leu.2401970. Leukemia. 2001. PMID: 11243381

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

355 results

Search Page